Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:IMTX NASDAQ:MDWD NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$12.61+4.4%$12.44$4.67▼$17.43$941.32M1.711.90 million shs2.32 million shsIMTXImmatics$5.90-3.3%$6.02$3.30▼$13.09$717.15M0.93767,778 shs791,338 shsMDWDMediWound$18.57-1.0%$19.76$14.14▼$22.50$200.71M0.2171,142 shs135,615 shsOCSOculis$17.83-1.2%$18.64$10.79▼$23.08$778.46M0.2745,774 shs6,624 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+5.04%+1.09%+6.34%+3.34%+219.58%IMTXImmatics-4.98%-3.79%-0.16%+30.06%-47.00%MDWDMediWound-0.11%+1.85%-8.40%-6.20%+2.97%OCSOculis-0.63%-1.07%-0.85%-1.61%+57.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix3.1981 of 5 stars4.41.00.00.02.50.01.9IMTXImmatics2.2506 of 5 stars3.63.00.00.01.71.70.0MDWDMediWound1.7221 of 5 stars3.51.00.00.01.90.80.6OCSOculis3.046 of 5 stars3.55.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$16.7132.48% UpsideIMTXImmatics 3.20Buy$14.67148.38% UpsideMDWDMediWound 3.00Buy$32.2573.34% UpsideOCSOculis 3.00Buy$35.3398.61% UpsideCurrent Analyst Ratings BreakdownLatest MDWD, CRMD, IMTX, and OCS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$20.00 ➝ $17.006/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/24/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.006/23/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/20/2025CRMDCorMedixRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.006/2/2025MDWDMediWoundOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$34.005/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/22/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.00 ➝ $31.00(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$121.48M7.75N/AN/A$2.96 per share4.26IMTXImmatics$168.65M4.26$0.22 per share26.28$5.12 per share1.15MDWDMediWound$19.21M10.47N/AN/A$2.89 per share6.44OCSOculis$780K995.78N/AN/A$1.91 per share9.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.7516.8213.42N/A42.11%42.73%34.19%10/29/2025 (Estimated)IMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%N/AMDWDMediWound-$30.22M-$2.09N/AN/AN/A-110.45%-74.12%-30.92%8/14/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)Latest MDWD, CRMD, IMTX, and OCS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/26/2025Q2 2025OCSOculis-$0.53N/AN/AN/A$0.14 millionN/A8/14/2025Q2 2025MDWDMediWound-$0.55-$1.23-$0.68-$1.23$5.68 millionN/A8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/7/2025Q2 2025CRMDCorMedix$0.20$0.28+$0.08$0.28$29.88 million$39.74 million5/21/2025Q1 2025MDWDMediWound-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A7.827.52IMTXImmaticsN/A10.2810.28MDWDMediWoundN/A2.151.99OCSOculisN/A4.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%IMTXImmatics64.41%MDWDMediWound46.83%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%IMTXImmatics3.30%MDWDMediWound9.20%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3074.65 million70.69 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableMDWDMediWound8010.81 million9.81 millionOptionableOCSOculis243.66 millionN/ANot OptionableMDWD, CRMD, IMTX, and OCS HeadlinesRecent News About These CompaniesPrivosegtor shows functional, anatomical improvements in patients with optic neuritisAugust 12 at 5:35 PM | healio.comHOculis Holding AG to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 12 at 4:10 AM | quiverquant.comQOculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 12 at 4:00 AM | globenewswire.comOculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 12 at 4:00 AM | globenewswire.comOculis Holding AG Secures Amended Loan Agreement with Kreos CapitalAugust 2, 2025 | msn.comOculis Holding AG Amends Loan Facility with BlackRock to Enhance Financial FlexibilityAugust 1, 2025 | quiverquant.comQOculis Upsized Loan Facility to Access up to CHF 100 millionAugust 1, 2025 | globenewswire.comOculis Upsized Loan Facility to Access up to CHF 100 millionAugust 1, 2025 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJuly 9, 2025 | globenewswire.comOCS - Oculis Holding AG Executives - MorningstarJuly 5, 2025 | morningstar.comMOculis Holding AG (OCS) - Yahoo FinanceJune 28, 2025 | sg.finance.yahoo.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | markets.businessinsider.comOculis Holding AG Announces Participation in Upcoming Investor Conferences in June 2025June 3, 2025 | quiverquant.comQOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis Holding AG: Oculis Reports Q1 Financial Results and Provides Company UpdateMay 11, 2025 | finanznachrichten.deOculis Publishes Invitation to the Annual General MeetingMay 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDWD, CRMD, IMTX, and OCS Company DescriptionsCorMedix NASDAQ:CRMD$12.61 +0.53 (+4.39%) Closing price 04:00 PM EasternExtended Trading$12.60 0.00 (-0.04%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Immatics NASDAQ:IMTX$5.90 -0.20 (-3.28%) Closing price 04:00 PM EasternExtended Trading$5.90 -0.01 (-0.08%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.MediWound NASDAQ:MDWD$18.57 -0.18 (-0.96%) Closing price 04:00 PM EasternExtended Trading$18.60 +0.04 (+0.19%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Oculis NASDAQ:OCS$17.83 -0.22 (-1.22%) Closing price 03:57 PM EasternExtended Trading$17.79 -0.04 (-0.22%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access